{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-22-000004","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2022-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.234902+00:00","generated_at":"2026-06-27T18:53:59.762998+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Veracyte appoints Tina Nova as President of CLIA U.S. business","bullets":["Tina S. Nova, Ph.D., appointed President of Veracyte's CLIA U.S. business effective January 6, 2022.","Dr. Nova previously served as General Manager, Thyroid and Urologic Cancers since March 2021.","She was on Veracyte's board from Nov 2015 to Feb 2021 and was CEO of Decipher before its acquisition.","Dr. Nova will enter into standard indemnification agreement; no family relationships or material transactions disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-22-000004","json":"https://secwatch.observer/filing/0001384101-22-000004.json","markdown":"https://secwatch.observer/filing/0001384101-22-000004.md","text":"https://secwatch.observer/filing/0001384101-22-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/0001384101-22-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/vcyt-20220106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:53:59.762998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8add4b4ab9","claim":"Tina S. Nova, Ph.D. was appointed as President of the Company’s CLIA U.S. business at VERACYTE, INC..","evidence_excerpt":"On January 6, 2022, Veracyte, Inc. (the “Company”), announced certain key leadership promotions including the appointment of Tina S. Nova, Ph.D., to serve as President of the Company’s CLIA U.S. business, effective as of January 6, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/0001384101-22-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President of the Company’s CLIA U.S. business"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}